Baseline patient characteristics
| Baseline patient characteristics | |
| Age (years) | 64±12 |
| Gender (male) | 58 (73) |
| Systolic blood pressure (mm Hg) | 122±18 |
| Heart rate (beats/min) | 71±11 |
| Weight (kg) | 90±22 |
| Estimated glomerular filtration rate (mL/min/1.73 m2) | 68±17 |
| Serum creatinine (mmol/L) | 97±27 |
| Serum potassium (mmol/L) | 4.6±0.4 |
| Ischaemic cardiomyopathy | 38 (48) |
| Left ventricular ejection fraction (%) | 26±7 |
| Left ventricular end systolic diameter (cm) | 5±1 |
| Left ventricular end diastolic diameter (cm) | 6±1 |
| NYHA I | 0 (0) |
| NYHA II | 59 (74) |
| NYHA III | 18 (22) |
| NYHA IV | 3 (4) |
| Mean Minnesota Living with Heart Failure Questionnaire | 45 (26) |
| Hypertension | 26 (33) |
| Diabetes | 17 (21) |
| Atrial fibrillation | 28 (35) |
| Cerebrovascular accident | 9 (11) |
| ACE inhibitor | 61 (76) |
| Angiotensin receptor blocker | 19 (24) |
| Beta blocker | 76 (95) |
| Mineralocorticoid receptor antagonist | 73 (91) |
| Loop diuretics | 42 (53) |
| Digitalis | 17 (21) |
| Nitrates | 9 (11) |
| Aspirin | 23 (29) |
| Clopidogrel/prasugrel/ticagrelor | 5 (6) |
| Warfarin | 20 (21) |
| Direct oral anticoagulant | 16 (20) |
| Statin | 55 (69) |
| CRT P | 4 (5) |
| CRT D | 27 (34) |
| Implantable cardioverter defibrillator | 10 (13) |
Categorical variables are expressed as number (percentage) and continuous variables are expressed as mean (SD) or median (IQR) depending on distribution.
CRT, cardiac resynchronisation therapy; NYHA, New York Heart Association.